33 results about "Active immunotherapy" patented technology

Modular aAPCs and methods of their manufacture and use are provided. The modular aAPCs are constructed from polymeric microparticles. The aAPCs include encapsulated cytokines and coupling agents which modularly couple functional elements including T cell receptor activators, co-stimulatory molecules and adhesion molecules to the particle. The ability of these aAPCs to release cytokines in a controlled manner, coupled with their modular nature and ease of ligand attachment, results in an ideal, tunable APC capable of stimulating and expanding primary T cells.

Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and / or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.

The invention relates to the fields of biotechnology and medicine, and provides a modified dendritic cell. Viral vectors are used to transfect an SYK gene into the modified dendritic cells. The invention also provides a vaccine with the modified dendritic cell as an active component. The vaccine is used for prevention and active immunotherapy of tumor. According to the invention, maturation of the DC cells transfected with the SYK gene, percentage and tumor killing rate of CD3 + CD56 + T cells in the obtained LV-DC-CIK cells, and IFN-gamma secretion rate in a cell culture supernatant are all significantly higher than those in a control group.

Predictive biomarkers identify those patients suffering from immunoglobulin positive (Ig+) B lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the CDR1 (herein termed CDR1-Y10) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of CDR1 tyrosine residues (herein termed CDR1-Yhi) is predictive of a low anti tumor response.

The invention belongs to the field of technical methods for preventing tumors, and in particular relates to a tumor microenvironment induced cancerous human umbilical vein endothelial cell vaccine andan application thereof in resisting angiogenesis of colon carcinoma. The vaccine is prepared by the following steps: collecting supernatant of CT26 cells, inducing HUVEC cells via the CT26 cell supernatant, collecting the HUVEC cells, immobilizing glutaraldehyde and the like. According to the invention, tumor vessel endothelial cells function as a target in tumor immnuotherapy, belonging to active immunotherapy. The cancerous HUVEC vaccine is prepared through inducing by an in-vitro simulated tumor microenvironment. Based upon preliminary experimental results, it is indicated that the prepared cancerous HUVEC vaccine can cause a more effective action in inhibiting tumor angiogenesis, and subsequently, an effect of resisting colon carcinoma growth can be developed; therefore, a relativelygood application effect can be achieved; and meanwhile, a new possibility is also provided for the application of a treatment method based on resisting tumor angiogenesis.

The invention provides a method for constructing an IL-33 presentation VLP (Virus-Like Particle) vaccine used in active immunotherapy of chronic asthma. The method comprises the following steps: extracting IL-33 total RNA (Ribonucleic Acid) from a mouse; performing reverse transcription to obtain IL33 total cDNA (complementary deoxyribonucleic acid); performing PCR (Polymerase Chain Reaction) amplification on the obtained total cDNA with a designed specific primer to obtain a coded IL-33 mature segment gene; inserting the gene between 78-bit amino acid and 79-bit amino acid of a hepatitis B virus core antigen HBcAg to obtain a recombinant plasmid pHBcAg33; transferring the plasmid onto escherichia coli DH5alpha or a BL21 competent cell; inducing by using IPTG (isopropyl-beta-d-thiogalactoside) and purifying to obtain the IL-33 presentation VLP vaccine. A strong neutralizing antibody which is specific to own molecules and has a durable action can be induced by inoculating the vaccine repeatedly in order to regulate and control immune response, thereby fulfilling the aim of regulating and controlling the progress of asthma.

The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and / or sorafenib tosylate or a pharmaceutically acceptable salt thereof.

The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.

The invention discloses a therapeutic interleukin-4 vaccine capable of treating human or animal tumor diseases. The therapeutic interleukin-4 vaccine is an any-form protein vaccine or conjugated protein vaccine prepared by taking a natural or artificially-synthesized intact protein or protein fragment of interleukin-4 as an antigen or an any-form gene vaccine or fused gene vaccine prepared by taking an intact gene or gene fragment of interleukin-4 as an antigen gene or main antigen gene. According to the invention, a host is subjected to active immunotherapy by using an IL-4 vaccine, generally, the effective time of the first immunity can be up to about 2-3 months, the effective treatment time of the second immunity can be up to about 6 months, and the rehabilitation aim can be achieved through carrying out immunotherapy for 1-3 times. Compared with a method for treating human or animal tumor diseases by directly applying an IL-4 antibody, the therapeutic interleukin-4 vaccine has the characteristics of low application frequency, small dosage and the like, so that not only is the treatment cost greatly reduced, but also the possibility for generating anaphylactic reaction is greatly reduced.